<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00208793</url>
  </required_header>
  <id_info>
    <org_study_id>0126-2004</org_study_id>
    <secondary_id>R01CA104637</secondary_id>
    <nct_id>NCT00208793</nct_id>
  </id_info>
  <brief_title>Calcium and Vitamin D vs Markers of Adenomatous Polyps</brief_title>
  <acronym>CaDvMAP</acronym>
  <official_title>Calcium, Vitamin D, and Colon Cancer Risk Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether calcium and/or vitamin D supplementation
      favorably affects a set of biomarkers of risk for colon cancer in persons who are at higher
      than average risk for colon cancer (ie, have already undergone the removal of adenomatous
      polyps, which are known to be precursors to developing colon cancer).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is strong biologic plausibility and animal experimental evidence for protection against
      colorectal cancer by calcium and vitamin D, calcium significantly reduced adenoma recurrence
      in a large clinical trial in humans (yet the previously reported observational evidence,
      although generally supportive, is inconsistent), and the observational literature strongly
      supports protection from vitamin D. A close physiological relationship between calcium and
      vitamin D has long been known. Yet, other than a possible reduction of colorectal epithelial
      cell proliferation by calcium, the effects of calcium and vitamin D, individually or jointly,
      on the normal human colorectal epithelium remain unknown. There have been no clinical trials
      involving vitamin D individually or jointly with calcium related to colorectal cancer
      chemoprevention in humans. There are currently no generally accepted pre-neoplastic
      biomarkers of risk for colorectal cancer other than the possible exception of proliferation
      markers that, at best, have limited usefulness as individual markers. Based on recent
      advances in understanding the molecular basis of colorectal cancer, we developed a panel of
      newer, plausible, reliable, immunohistochemically detected biomarkers that provides molecular
      phenotyping of the normal appearing colorectal epithelium: 1) inflammation (COX-2), 2) the
      expression of genes involved in the normal structure and function of the colorectal
      epithelium that have been found to be altered early in the two major colorectal
      carcinogenesis pathways (APC, MSH2, MLH1), and 3) a more complete picture of the cell cycle
      events in colorectal epithelial crypt cells (short and long-term proliferation: MIB-1 and
      telomerase; differentiation: p21; apoptosis inhibition and promotion: bcl-2, bax, and bak)
      that has not yet been tested in a chemoprevention trial.

      To address these needs, we will conduct a preliminary, randomized, double-blind,
      placebo-controlled, 2 x 2 factorial chemoprevention trial (n = 88) of calcium 2,000 mg/day
      and vitamin D3 800 IU/day, alone and in combination vs placebo over 6 months in patients with
      recent removal of sporadic adenomatous colorectal polyps, to investigate their effects on the
      individual components and aggregate profile of our colorectal cancer risk biomarker panel. We
      will also examine study results stratified by NSAID use and Bsm I vitamin D receptor
      genotypes. The preliminary estimates of treatment effect sizes and variabilities will be used
      to refine the biomarker panel and study design and to calculate the needed sample size for a
      potential full-scale study.

      We assert that using biological measurements of risk, as they have for ischemic heart
      disease, will result in a decline in colorectal cancer incidence and mortality. The proposed
      project is borne of this vision, and has intertwined missions of exploring the efficacy of
      two plausible and evidentially well-supported dietary agents, calcium and vitamin D, on the
      modulation of a plausible panel of molecular phenotypic biomarkers of risk for colorectal
      neoplasia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers of Risk for Colorectal Neoplasms</measure>
    <time_frame>6 months</time_frame>
    <description>A panel of putative biomarkers of risk for colorectal neoplasms in biopsies of normal appearing rectal mucosa: COX-2, APC, MSH-2, MLH1, MIB-1, telomerase, p21, bcl-2, bax, bak, β-catenin, E-cadherin, TGFα, TGFβ1, calcium sensing receptor, vitamin D receptor, CYP27B1, CYP24, 8-OH-dG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vitamin D metabolites</measure>
    <time_frame>6 months</time_frame>
    <description>serum 25-OH-vitamin D3 and 1,25-OH-vitamin D3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammation markers</measure>
    <time_frame>6 months</time_frame>
    <description>serum CRP, TNF-α, IL-6, IL-1β, IL-8 and IL-10</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Colorectal Adenomatous Polyps</condition>
  <arm_group>
    <arm_group_label>Calcium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcium 2,000 mg/day as calcium carbonate in two divided doses with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium and vitamin D3 combined</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with meals over 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium and vitamin D3 combined</intervention_name>
    <description>Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with food over 6 months</description>
    <arm_group_label>Calcium and vitamin D3 combined</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium</intervention_name>
    <description>Calcium 2,000 mg/day as calcium carbonate in two divided doses with meals over 6 months</description>
    <arm_group_label>Calcium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months</description>
    <arm_group_label>Vitamin D3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 30-74

          -  adenomatous colon polyp within past 3 years

          -  general good health with life expectancy of at least 2 years

          -  available for 8 months and able to come for clinic visits

        Exclusion Criteria:

          -  cancer within 5 years

          -  active major disease

          -  renal impairment

          -  history of kidney stones

          -  significant dietary change or weight loss within past 6 months

          -  unable to forego usual calcium or vitamin D use during study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberd M Bostick, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University, Rollins School of Public Health &amp; Winship Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Emory Clinic, Division of Digestive Diseases</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Fedirko V, Bostick RM, Flanders WD, Long Q, Shaukat A, Rutherford RE, Daniel CR, Cohen V, Dash C. Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial. Cancer Prev Res (Phila). 2009 Mar;2(3):213-23. doi: 10.1158/1940-6207.CAPR-08-0157. Epub 2009 Mar 3.</citation>
    <PMID>19258546</PMID>
  </results_reference>
  <results_reference>
    <citation>Fedirko V, Bostick RM, Flanders WD, Long Q, Sidelnikov E, Shaukat A, Daniel CR, Rutherford RE, Woodard JJ. Effects of vitamin d and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2933-41. doi: 10.1158/1055-9965.EPI-09-0239. Epub 2009 Oct 27.</citation>
    <PMID>19861511</PMID>
  </results_reference>
  <results_reference>
    <citation>McCullough ML, Bostick RM, Daniel CR, Flanders WD, Shaukat A, Davison J, Rangaswamy U, Hollis BW. Vitamin D status and impact of vitamin D3 and/or calcium supplementation in a randomized pilot study in the Southeastern United States. J Am Coll Nutr. 2009 Dec;28(6):678-86.</citation>
    <PMID>20516268</PMID>
  </results_reference>
  <results_reference>
    <citation>Fedirko V, Bostick RM, Long Q, Flanders WD, McCullough ML, Sidelnikov E, Daniel CR, Rutherford RE, Shaukat A. Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):280-91. doi: 10.1158/1055-9965.EPI-09-0448.</citation>
    <PMID>20056649</PMID>
  </results_reference>
  <results_reference>
    <citation>Sidelnikov E, Bostick RM, Flanders WD, Long Q, Fedirko V, Shaukat A, Daniel CR, Rutherford RE. Effects of calcium and vitamin D on MLH1 and MSH2 expression in rectal mucosa of sporadic colorectal adenoma patients. Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1022-32. doi: 10.1158/1055-9965.EPI-09-0526. Epub 2010 Mar 23.</citation>
    <PMID>20332274</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahearn TU, McCullough ML, Flanders WD, Long Q, Sidelnikov E, Fedirko V, Daniel CR, Rutherford RE, Shaukat A, Bostick RM. A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients. Cancer Res. 2011 Jan 15;71(2):413-23. doi: 10.1158/0008-5472.CAN-10-1560. Epub 2010 Nov 17.</citation>
    <PMID>21084270</PMID>
  </results_reference>
  <results_reference>
    <citation>Hopkins MH, Owen J, Ahearn T, Fedirko V, Flanders WD, Jones DP, Bostick RM. Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial. Cancer Prev Res (Phila). 2011 Oct;4(10):1645-54. doi: 10.1158/1940-6207.CAPR-11-0105. Epub 2011 Jun 30.</citation>
    <PMID>21724580</PMID>
  </results_reference>
  <results_reference>
    <citation>Chai W, Bostick RM, Ahearn TU, Franke AA, Custer LJ, Cooney RV. Effects of vitamin D3 and calcium supplementation on serum levels of tocopherols, retinol, and specific vitamin D metabolites. Nutr Cancer. 2012;64(1):57-64. doi: 10.1080/01635581.2012.630552. Epub 2011 Dec 9.</citation>
    <PMID>22149065</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahearn TU, Shaukat A, Flanders WD, Rutherford RE, Bostick RM. A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on the APC/β-catenin pathway in the normal mucosa of colorectal adenoma patients. Cancer Prev Res (Phila). 2012 Oct;5(10):1247-56. doi: 10.1158/1940-6207.CAPR-12-0292. Epub 2012 Sep 10.</citation>
    <PMID>22964475</PMID>
  </results_reference>
  <results_reference>
    <citation>Hopkins MH, Flanders WD, Bostick RM. Associations of circulating inflammatory biomarkers with risk factors for colorectal cancer in colorectal adenoma patients. Biomark Insights. 2012;7:143-50. doi: 10.4137/BMI.S10092. Epub 2012 Nov 5.</citation>
    <PMID>23170065</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>November 22, 2013</last_update_submitted>
  <last_update_submitted_qc>November 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Roberd Bostick, MD, MPH</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>colonic polyps</keyword>
  <keyword>adenomatous polyps</keyword>
  <keyword>colon cancer prevention</keyword>
  <keyword>dietary supplements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Adenomatous Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

